Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20698622 | 0.91 | HIF1A (0.50) | HIF1APTGS2 | |
| SCHEMBL20699003 | 0.90 | HIF1A (0.38) | HIF1AF10PTGS2 | |
| SCHEMBL20698999 | 0.86 | HIF1A (0.36) | HIF1AF10PTGS2 | |
| SCHEMBL20699002 | 0.86 | HIF1A (0.36) | HIF1A | |
| SCHEMBL20699049 | 0.86 | HIF1A (0.35) | HIF1A | |
| SCHEMBL20699048 | 0.85 | HIF1A (0.33) | HIF1APTGS2L3MBTL1RAB9AHPGD | |
| SCHEMBL20698629 | 0.84 | HIF1A (0.35) | HIF1A | |
| SCHEMBL20698619 | 0.84 | HIF1A (0.35) | HIF1A | |
| SCHEMBL20698624 | 0.82 | HIF1A (0.49) | HIF1ASMN1; SMN2 | |
| SCHEMBL20698671 | 0.82 | HIF1A (0.40) | HIF1APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | NANKAI UNIVERSITY (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | NANKAI UNIVERSITY (CN) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906880-B2 | Kind of isothiazole oxime ether-containing strobilurin derivatives and its preparation methods and application | STS, STAU1, CDV3 | HIF1A 3135/4885F10 3297/4885PTGS2 4753/4885 |
| US-20190031627-A1 | A KIND OF ISOTHIAZOLE OXIME ETHER-CONTAINING STROBILURIN DERIVATIVES AND ITS PREPARATION METHODS AND APPLICATION | STS, CDV3, SALL4 | HIF1A 3136/4885F10 3509/4885PTGS2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.